Agenda

NMSG Plenary Autumn Meeting 2019

Time: Thursday the 5th and Friday the 6th of September
Venue: Clarion Hotel Copenhagen Airport

Myeloma school for nurses starts at 10.00 (see separate program).

Welcome for working groups - Plenary room (Annette Vangsted)

Educational and scientific working groups for doctors at 10.00 – 12.00

Translational group (Niels Abildgaard)	Room: JORD
Cellular therapy group (Nicolai Grønne Dahlager Jørgensen)	Room: VIDAR
Clinical trial group (Fredrik Schjesvold)	Room: THOR
QoL and PRO group (Lene Kongsgaard)	Room: BOR
Real World Data group (RWD) (Cecilie Hveding)	Room: ODIN

Thursday 5 Sep. Meeting for NMSG members and companies

12.00-13.00 *Registration in front of the meeting room + Standing sandwich lunch and coffee for companies and NMSG members in meeting foyer (ground floor)*

13.00-13.10 Welcome (*Annette Vangsted*)
13.10-14.30 Abstract presentations
13.10-13.25 Lene Kongsgaard Nielsen: Half of patients with multiple myeloma with rehabilitation needs report moderate to severe symptoms or functional problems
13.25-13.40 Henrik Rode Eshøj et al. Timing of patient-reported outcome assessment of transient symptomatic toxicities from myeloma treatment seem to matter- finding from an NMSG phase II relapse trial
13.40-13.55 Johanna Borg Bruchfeld el al. Upfront bortezomib, lenalidomide and dexamethasone compared to bortezomib, cyclophosphamide and dexamethasone in multiple myeloma
13.55-14.10 Agoston Gyula Szabo et al. clinical suspected cast nephropathy a retrospective, multi-center, real-world study
14.10-14.25 15.00-15.15 Agoston Gyula Szabo et al. The clinical course of multiple myeloma in the era of novel agents: a retrospective, single-center, real-world study

14.30-15.00 *Coffee break in meeting foyer (ground floor)*

15.00-16.00 Abstract presentations continued
15.15-15.30 Louise Redder et al. Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry
15.30-15.45 Ankita Agrawal et al. P2RX7 in multiple myeloma
15.45-16.00 Niels Abildgaard et al. Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits
16.00-17.00 Guideline for treatment in the NMSG countries

17.00-17.15 *Coffee break in meeting foyer (ground floor)*

17.15-18.15 Presentation of new studies that will start soon (Fredrik Schjesvold)
18.15-18.45 Business Meeting, economy, regulations (NMSG members only)

19.15-21.30 *Dinner in "Ellehammer 2" at the venue (for those who signed up through the registration site)*

Friday 6 Sep.

08.30-09.00 *Morning coffee in meeting foyer (ground floor)*

09.00-09.30 Experience of BiTe treatment in Lymphoma at Rigshospitalet, Martin Hutchings

09.30-11.30 Investigator meeting for NMSG studies. Status finalized, ongoing and new studies;
For each: 10 min presentation and 10 min discussion

- NMSG 20/13, CARFI study (Henrik Gregersen)
- NMSG 21/13, Ixazomib-Thalidomide-Dex in newly diagnosed elderly (Niels Abildgaard)
- NMSG 22/14, Zoledronic Acid study, the Magnolia study (Thomas Lund)
- NMSG 23/15, IRD for NDMM (Raija Silvennoinen)
- NMSG 24/15, KED for RRMM (Raija Silvennoinen)
- NMSG 25/16 The CONPET study (Fredrik Schjesvold)
- NMSG -COPRA study, (CRd versus VRd) (Valdas Peceliunas)
- The Mermaid study (Agoston Gyula Szabo)
- The Persius study, (Annette Vangsted)

11.30-12.30 *Lunch in the restaurant (ground floor)*

12.30-14.30 NMSG working groups.
Presentation from the translations reseach group (Niels Abildgaard)
Presentation from the cellular therapy group (Nicolai Grønne Dahlager Jørgensen)
Presentation from our clinical trial group (Fredrik Schjesvold)
Presentation from the RWD group (Cecilie Hveding)
Presentation from the QoL and PRO group (Lene Kongsgaard)

14.30 Discussion on integration of the working groups in clinical trials

15.00 *End of meeting, see you next time*

The meeting is kindly sponsored by:

AMGEN

AH diagnostics

Bristol-Myers Squibb

Binding Site THE BINDING SITE

abbvie

Celgene

janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

SANOFI GENZYME

Takeda